腎臓がんの世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）
Kidney Cancer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
- レポートID：80038
- 発表時期：2026-01-05
- レポート形式：PDF
- 産業カテゴリー：薬品及びサプリメント
- レポート言語：英語、日本語
- ページ数：117
- 発行会社（調査会社）：QYResearch
言語とエディションの価格
- 英語版
- 日本語版
- 英語と日本語版
個人版詳細
マルチユーザー版詳細
企業版詳細
- 英語版
- 日本語版
- 英語と日本語版
価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。
※米ドル表示価格+10％消費税。
※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
レポートの概要
本報告書は、世界の腎臓がん市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点から腎臓がん市場を分析し、需要構造と成長特性を明確化します。
腎臓がん市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、腎臓がんに関する的確な意思決定を行うための実践的なインサイトを提供します。
主要腎臓がん市場の統計
2025年世界市場規模：12160百万米ドル
2026年世界市場規模：12860百万米ドル
2032年予測市場規模：18570百万米ドル
2026–2032年予測期間CAGR：6.3%
本レポートは腎臓がん市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。
【市場セグメンテーション】
主要企業・競争環境
腎臓がん市場の主要企業には以下が含まれます：
Merck
Novartis
Bristol-Myers Squibb
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Bayer
Exelixis
Eisai
Hikma Pharmaceuticals
Sun Pharmaceutical
製品別
Surgery
Immunotherapy
Targeted Therapy
Other
アプリケーション別
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他
レポート構成（章別概要）
第1章｜市場概要と成長展望
腎臓がん市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
腎臓がん市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別に腎臓がん市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別に腎臓がん市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、腎臓がん市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、腎臓がん市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
腎臓がん市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します
本レポートの要点と洞察
●腎臓がん市場の全体像と成長見通し
腎臓がん市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境が腎臓がん市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
腎臓がん産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
腎臓がん市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点から腎臓がん市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
腎臓がん市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
腎臓がん市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
Description
The global market for Kidney Cancer was estimated to be worth US$ 12160 million in 2025 and is projected to reach US$ 18570 million, growing at a CAGR of 6.3% from 2026 to 2032.
Kidney cancer therapy refers to a range of medical treatments aimed at managing or eradicating cancerous cells in the kidneys. These treatments include surgery (such as nephrectomy), targeted therapy, immunotherapy, radiation therapy, and, in some cases, chemotherapy. The choice of therapy depends on the type, stage, and progression of the cancer, as well as the patient’s overall health. The primary goals are to control the disease, prolong survival, and improve the patient’s quality of life.
Market Drivers for Kidney Cancer:
Increasing Prevalence of Kidney Cancer: Rising cases of kidney cancer worldwide, driven by aging populations and lifestyle-related factors, are boosting the demand for effective diagnostic and therapeutic solutions.
Advancements in Treatment Options: Innovations in targeted therapies, immunotherapies, and minimally invasive surgical techniques are improving patient outcomes, driving market growth.
Growing Awareness and Early Diagnosis: Enhanced awareness campaigns and improved screening technologies are leading to earlier detection, which increases the demand for treatments.
Supportive Government Policies and Funding: Increased investments in cancer research and supportive healthcare policies are fostering market expansion.
Market Challenges for Kidney Cancer:
High Treatment Costs: The expensive nature of advanced therapies, including immunotherapy and targeted drugs, limits accessibility for some patients, particularly in developing regions.
Side Effects and Resistance to Therapies: Adverse effects of treatments and the potential development of resistance to targeted drugs pose significant clinical and market challenges.
Limited Accessibility in Low-Income Regions: Inadequate healthcare infrastructure and limited access to advanced treatments in certain regions hinder market penetration.
Regulatory Hurdles: Stringent regulatory requirements for the approval of new drugs and therapies may delay market entry and development.
Global key players of Kidney Cancer include Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, etc. Global top four manufacturers hold a share over 35%. North America has the largest number of Kidney cancer, holds a share of about 50%. In terms of product, targeted therapy is the largest segment, with a share over 45%. And in terms of application, the largest application is renal cell carcinoma, with a share of over 90%.
This report provides a comprehensive view of the global market for Kidney Cancer, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Kidney Cancer market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Kidney Cancer.
Market Segmentation
By Company
Merck
Novartis
Bristol-Myers Squibb
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Bayer
Exelixis
Eisai
Hikma Pharmaceuticals
Sun Pharmaceutical
Segment by Type
Surgery
Immunotherapy
Targeted Therapy
Other
Segment by Application
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.
Chapter 2: Provides a detailed analysis of the Kidney Cancer companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Kidney Cancer revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Kidney Cancer revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.
Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Kidney Cancer Product Introduction
1.2 Global Kidney Cancer Market Size Forecast (2021–2032)
1.3 Kidney Cancer Market Trends & Drivers
1.3.1 Kidney Cancer Industry Trends
1.3.2 Kidney Cancer Market Drivers & Opportunities
1.3.3 Kidney Cancer Market Challenges
1.3.4 Kidney Cancer Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Kidney Cancer Players Revenue Ranking (2025)
2.2 Global Kidney Cancer Revenue by Company (2021–2026)
2.3 Key Companies’ R&D and Operations Footprint and Headquarters
2.4 Key Companies Kidney Cancer Product Offerings
2.5 Key Companies General Availability (GA) Timeline for Kidney Cancer
2.6 Kidney Cancer Market Competitive Analysis
2.6.1 Kidney Cancer Market Concentration Rate (2021–2026)
2.6.2 Top 5 and Top 10 Global Companies by Kidney Cancer Revenue in 2025
2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Kidney Cancer revenue, 2025
2.7 Mergers & Acquisitions and Expansion
3 Segmentation Kidney Cancer Market Classification
3.1 Introduction by Type
3.1.1 Surgery
3.1.2 Immunotherapy
3.1.3 Targeted Therapy
3.1.4 Other
3.1.5 Global Kidney Cancer Sales Value by Type
3.1.5.1 Global Kidney Cancer Sales Value by Type (2021 vs 2025 vs 2032)
3.1.5.2 Global Kidney Cancer Sales Value, by Type (2021–2032)
3.1.5.3 Global Kidney Cancer Sales Value, by Type (%), 2021–2032
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Renal Cell Carcinoma
4.1.2 Renal Pelvis Cancer
4.1.3 Other
4.2 Global Kidney Cancer Sales Value by Application
4.2.1 Global Kidney Cancer Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Kidney Cancer Sales Value by Application (2021–2032)
4.2.3 Global Kidney Cancer Sales Value by Application (%), 2021–2032
5 Segmentation by Region
5.1 Global Kidney Cancer Sales Value by Region
5.1.1 Global Kidney Cancer Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Kidney Cancer Sales Value by Region (2021–2026)
5.1.3 Global Kidney Cancer Sales Value by Region (2027–2032)
5.1.4 Global Kidney Cancer Sales Value by Region (%), 2021–2032
5.2 North America
5.2.1 North America Kidney Cancer Sales Value, 2021–2032
5.2.2 North America Kidney Cancer Sales Value by Country (%), 2025 vs 2032
5.3 Europe
5.3.1 Europe Kidney Cancer Sales Value, 2021–2032
5.3.2 Europe Kidney Cancer Sales Value by Country (%), 2025 vs 2032
5.4 Asia Pacific
5.4.1 Asia Pacific Kidney Cancer Sales Value, 2021–2032
5.4.2 Asia Pacific Kidney Cancer Sales Value by Subregion (%), 2025 vs 2032
5.5 South America
5.5.1 South America Kidney Cancer Sales Value, 2021–2032
5.5.2 South America Kidney Cancer Sales Value by Country (%), 2025 vs 2032
5.6 Middle East & Africa
5.6.1 Middle East & Africa Kidney Cancer Sales Value, 2021–2032
5.6.2 Middle East & Africa Kidney Cancer Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Kidney Cancer Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Kidney Cancer Sales Value, 2021–2032
6.3 United States
6.3.1 United States Kidney Cancer Sales Value, 2021–2032
6.3.2 United States Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Kidney Cancer Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Kidney Cancer Sales Value, 2021–2032
6.4.2 Europe Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Kidney Cancer Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Kidney Cancer Sales Value, 2021–2032
6.5.2 China Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.5.3 China Kidney Cancer Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Kidney Cancer Sales Value, 2021–2032
6.6.2 Japan Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Kidney Cancer Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Kidney Cancer Sales Value, 2021–2032
6.7.2 South Korea Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Kidney Cancer Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Kidney Cancer Sales Value, 2021–2032
6.8.2 Southeast Asia Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Kidney Cancer Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Kidney Cancer Sales Value, 2021–2032
6.9.2 India Kidney Cancer Sales Value by Type (%), 2025 vs 2032
6.9.3 India Kidney Cancer Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Merck
7.1.1 Merck Profile
7.1.2 Merck Main Business
7.1.3 Merck Kidney Cancer Products, Services, and Solutions
7.1.4 Merck Kidney Cancer Revenue (US$ Million), 2021–2026
7.1.5 Merck Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis Kidney Cancer Products, Services, and Solutions
7.2.4 Novartis Kidney Cancer Revenue (US$ Million), 2021–2026
7.2.5 Novartis Recent Developments
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Profile
7.3.2 Bristol-Myers Squibb Main Business
7.3.3 Bristol-Myers Squibb Kidney Cancer Products, Services, and Solutions
7.3.4 Bristol-Myers Squibb Kidney Cancer Revenue (US$ Million), 2021–2026
7.3.5 Bristol-Myers Squibb Recent Developments
7.4 Pfizer
7.4.1 Pfizer Profile
7.4.2 Pfizer Main Business
7.4.3 Pfizer Kidney Cancer Products, Services, and Solutions
7.4.4 Pfizer Kidney Cancer Revenue (US$ Million), 2021–2026
7.4.5 Pfizer Recent Developments
7.5 Roche
7.5.1 Roche Profile
7.5.2 Roche Main Business
7.5.3 Roche Kidney Cancer Products, Services, and Solutions
7.5.4 Roche Kidney Cancer Revenue (US$ Million), 2021–2026
7.5.5 Roche Recent Developments
7.6 Amgen
7.6.1 Amgen Profile
7.6.2 Amgen Main Business
7.6.3 Amgen Kidney Cancer Products, Services, and Solutions
7.6.4 Amgen Kidney Cancer Revenue (US$ Million), 2021–2026
7.6.5 Amgen Recent Developments
7.7 Aveo Pharmaceuticals
7.7.1 Aveo Pharmaceuticals Profile
7.7.2 Aveo Pharmaceuticals Main Business
7.7.3 Aveo Pharmaceuticals Kidney Cancer Products, Services, and Solutions
7.7.4 Aveo Pharmaceuticals Kidney Cancer Revenue (US$ Million), 2021–2026
7.7.5 Aveo Pharmaceuticals Recent Developments
7.8 Bayer
7.8.1 Bayer Profile
7.8.2 Bayer Main Business
7.8.3 Bayer Kidney Cancer Products, Services, and Solutions
7.8.4 Bayer Kidney Cancer Revenue (US$ Million), 2021–2026
7.8.5 Bayer Recent Developments
7.9 Exelixis
7.9.1 Exelixis Profile
7.9.2 Exelixis Main Business
7.9.3 Exelixis Kidney Cancer Products, Services, and Solutions
7.9.4 Exelixis Kidney Cancer Revenue (US$ Million), 2021–2026
7.9.5 Exelixis Recent Developments
7.10 Eisai
7.10.1 Eisai Profile
7.10.2 Eisai Main Business
7.10.3 Eisai Kidney Cancer Products, Services, and Solutions
7.10.4 Eisai Kidney Cancer Revenue (US$ Million), 2021–2026
7.10.5 Eisai Recent Developments
7.11 Hikma Pharmaceuticals
7.11.1 Hikma Pharmaceuticals Profile
7.11.2 Hikma Pharmaceuticals Main Business
7.11.3 Hikma Pharmaceuticals Kidney Cancer Products, Services, and Solutions
7.11.4 Hikma Pharmaceuticals Kidney Cancer Revenue (US$ Million), 2021–2026
7.11.5 Hikma Pharmaceuticals Recent Developments
7.12 Sun Pharmaceutical
7.12.1 Sun Pharmaceutical Profile
7.12.2 Sun Pharmaceutical Main Business
7.12.3 Sun Pharmaceutical Kidney Cancer Products, Services, and Solutions
7.12.4 Sun Pharmaceutical Kidney Cancer Revenue (US$ Million), 2021–2026
7.12.5 Sun Pharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Kidney Cancer Value Chain
8.2 Kidney Cancer Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Cost Structure
8.3 Midstream Analysis
8.4 Downstream (Customer) Analysis
8.5 Sales Model and Sales Channelss
8.5.1 Kidney Cancer Sales Model
8.5.2 Sales Channels
8.5.3 Kidney Cancer Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
Table of Figures
List of Tables Table 1. Kidney Cancer Market Trends Table 2. Kidney Cancer Market Drivers & Opportunities Table 3. Kidney Cancer Market Challenges Table 4. Kidney Cancer Market Restraints Table 5. Global Kidney Cancer Revenue by Company (US$ Million), 2021–2026 Table 6. Global Kidney Cancer Revenue Market Share by Company (2021–2026) Table 7. Key Companies’ R&D and Operations Footprint and Headquarters Table 8. Key Companies Kidney Cancer Product Type Table 9. Key Companies General Availability (GA) Timeline for Kidney Cancer Table 10. Global Kidney Cancer Companies Market Concentration Ratio (CR5 and HHI) Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Kidney Cancer revenue, 2025 Table 12. Mergers & Acquisitions and Expansion Plans Table 13. Global Kidney Cancer Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million) Table 14. Global Kidney Cancer Sales Value by Type (US$ Million), 2021–2026 Table 15. Global Kidney Cancer Sales Value by Type (US$ Million), 2027–2032 Table 16. Global Kidney Cancer Sales Market Share in Value by Type (2021–2026) Table 17. Global Kidney Cancer Sales Market Share in Value by Type (2027–2032) Table 18. Global Kidney Cancer Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million) Table 19. Global Kidney Cancer Sales Value by Application (US$ Million), 2021–2026 Table 20. Global Kidney Cancer Sales Value by Application (US$ Million), 2027–2032 Table 21. Global Kidney Cancer Sales Market Share in Value by Application (2021–2026) Table 22. Global Kidney Cancer Sales Market Share in Value by Application (2027–2032) Table 23. Global Kidney Cancer Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032 Table 24. Global Kidney Cancer Sales Value by Region (US$ Million), 2021–2026 Table 25. Global Kidney Cancer Sales Value by Region (US$ Million), 2027–2032 Table 26. Global Kidney Cancer Sales Value by Region (%), 2021–2026 Table 27. Global Kidney Cancer Sales Value by Region (%), 2027–2032 Table 28. Key Countries/Regions Kidney Cancer Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032 Table 29. Key Countries/Regions Kidney Cancer Sales Value, (US$ Million), 2021–2026 Table 30. Key Countries/Regions Kidney Cancer Sales Value, (US$ Million), 2027–2032 Table 31. Merck Basic Information List Table 32. Merck Description and Business Overview Table 33. Merck Kidney Cancer Products, Services, and Solutions Table 34. Revenue (US$ Million) in Kidney Cancer Business of Merck (2021–2026) Table 35. Merck Recent Developments Table 36. Novartis Basic Information List Table 37. Novartis Description and Business Overview Table 38. Novartis Kidney Cancer Products, Services, and Solutions Table 39. Revenue (US$ Million) in Kidney Cancer Business of Novartis (2021–2026) Table 40. Novartis Recent Developments Table 41. Bristol-Myers Squibb Basic Information List Table 42. Bristol-Myers Squibb Description and Business Overview Table 43. Bristol-Myers Squibb Kidney Cancer Products, Services, and Solutions Table 44. Revenue (US$ Million) in Kidney Cancer Business of Bristol-Myers Squibb (2021–2026) Table 45. Bristol-Myers Squibb Recent Developments Table 46. Pfizer Basic Information List Table 47. Pfizer Description and Business Overview Table 48. Pfizer Kidney Cancer Products, Services, and Solutions Table 49. Revenue (US$ Million) in Kidney Cancer Business of Pfizer (2021–2026) Table 50. Pfizer Recent Developments Table 51. Roche Basic Information List Table 52. Roche Description and Business Overview Table 53. Roche Kidney Cancer Products, Services, and Solutions Table 54. Revenue (US$ Million) in Kidney Cancer Business of Roche (2021–2026) Table 55. Roche Recent Developments Table 56. Amgen Basic Information List Table 57. Amgen Description and Business Overview Table 58. Amgen Kidney Cancer Products, Services, and Solutions Table 59. Revenue (US$ Million) in Kidney Cancer Business of Amgen (2021–2026) Table 60. Amgen Recent Developments Table 61. Aveo Pharmaceuticals Basic Information List Table 62. Aveo Pharmaceuticals Description and Business Overview Table 63. Aveo Pharmaceuticals Kidney Cancer Products, Services, and Solutions Table 64. Revenue (US$ Million) in Kidney Cancer Business of Aveo Pharmaceuticals (2021–2026) Table 65. Aveo Pharmaceuticals Recent Developments Table 66. Bayer Basic Information List Table 67. Bayer Description and Business Overview Table 68. Bayer Kidney Cancer Products, Services, and Solutions Table 69. Revenue (US$ Million) in Kidney Cancer Business of Bayer (2021–2026) Table 70. Bayer Recent Developments Table 71. Exelixis Basic Information List Table 72. Exelixis Description and Business Overview Table 73. Exelixis Kidney Cancer Products, Services, and Solutions Table 74. Revenue (US$ Million) in Kidney Cancer Business of Exelixis (2021–2026) Table 75. Exelixis Recent Developments Table 76. Eisai Basic Information List Table 77. Eisai Description and Business Overview Table 78. Eisai Kidney Cancer Products, Services, and Solutions Table 79. Revenue (US$ Million) in Kidney Cancer Business of Eisai (2021–2026) Table 80. Eisai Recent Developments Table 81. Hikma Pharmaceuticals Basic Information List Table 82. Hikma Pharmaceuticals Description and Business Overview Table 83. Hikma Pharmaceuticals Kidney Cancer Products, Services, and Solutions Table 84. Revenue (US$ Million) in Kidney Cancer Business of Hikma Pharmaceuticals (2021–2026) Table 85. Hikma Pharmaceuticals Recent Developments Table 86. Sun Pharmaceutical Basic Information List Table 87. Sun Pharmaceutical Description and Business Overview Table 88. Sun Pharmaceutical Kidney Cancer Products, Services, and Solutions Table 89. Revenue (US$ Million) in Kidney Cancer Business of Sun Pharmaceutical (2021–2026) Table 90. Sun Pharmaceutical Recent Developments Table 91. Revenue (US$ Million) in Kidney Cancer Business of Company 40 (2021–2026) Table 92. Company 40 Recent Developments Table 93. Key Raw Materials Lists Table 94. Key Suppliers of Raw Materials Lists Table 95. Kidney Cancer Downstream Customers Table 96. Kidney Cancer Distributors List Table 97. Research Programs/Design for This Report Table 98. Key Data Information from Secondary Sources Table 99. Key Data Information from Primary Sources List of Figures Figure 1. Kidney Cancer Product Picture Figure 2. Global Kidney Cancer Sales Value, 2021 vs 2025 vs 2032 (US$ Million) Figure 3. Global Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 4. Kidney Cancer Report Years Considered Figure 5. Global Kidney Cancer Players Revenue Ranking (US$ Million), 2025 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Kidney Cancer Revenue in 2025 Figure 7. Kidney Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025 Figure 8. Surgery Picture Figure 9. Immunotherapy Picture Figure 10. Targeted Therapy Picture Figure 11. Other Picture Figure 12. Global Kidney Cancer Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032 Figure 13. Global Kidney Cancer Sales Value Market Share by Type, 2025 & 2032 Figure 14. Product Picture of Renal Cell Carcinoma Figure 15. Product Picture of Renal Pelvis Cancer Figure 16. Product Picture of Other Figure 17. Global Kidney Cancer Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032 Figure 18. Global Kidney Cancer Sales Value Market Share by Application, 2025 & 2032 Figure 19. North America Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 20. North America Kidney Cancer Sales Value by Country (%), 2025 vs 2032 Figure 21. Europe Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 22. Europe Kidney Cancer Sales Value by Country (%), 2025 vs 2032 Figure 23. Asia Pacific Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 24. Asia Pacific Kidney Cancer Sales Value by Subregion (%), 2025 vs 2032 Figure 25. South America Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 26. South America Kidney Cancer Sales Value by Country (%), 2025 vs 2032 Figure 27. Middle East & Africa Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 28. Middle East & Africa Kidney Cancer Sales Value by Country (%), 2025 vs 2032 Figure 29. Key Countries/Regions Kidney Cancer Sales Value (%), 2021–2032 Figure 30. United States Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 31. United States Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 32. United States Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 33. Europe Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 34. Europe Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 35. Europe Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 36. China Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 37. China Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 38. China Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 39. Japan Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 40. Japan Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 41. Japan Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 42. South Korea Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 43. South Korea Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 44. South Korea Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 45. Southeast Asia Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 46. Southeast Asia Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 47. Southeast Asia Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 48. India Kidney Cancer Sales Value (US$ Million), 2021–2032 Figure 49. India Kidney Cancer Sales Value by Type (%), 2025 vs 2032 Figure 50. India Kidney Cancer Sales Value by Application (%), 2025 vs 2032 Figure 51. Kidney Cancer Value Chain Figure 52. Kidney Cancer Cost Structure Figure 53. Channels of Distribution (Direct Sales, and Distribution) Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed
お見積>
サンプルお申込み>
今すぐ購入>
PDFダウンロード>
当社から購入のメリット
多言語（英語、日本語）のサンプル提供
プロフェッショナルな日本語翻訳を提供
請求書、クレジットカードでのお支払いが可能です
必要なチャプターやカスタマイズされたレポートの注文が可能
購入後、アナリストに直接連絡することができます
購入方法
必要な言語とバージョンのレポート選択
レポート要件と見積もり依頼
電子メールによる注文
レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）
クレジットカード決済、オフライン振込に対応（後払い可）
クライアント様（例）
050-5840-2692 日本
0081-50-5840-2692 グローバル
info@globalreports.jp